9-nitro-(20R)-camptothecin | 151636-74-7

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 喜树碱
• 英文名称: 9-nitro-(20R)-camptothecin
• 英文别名: (19R)-19-ethyl-19-hydroxy-8-nitro-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione
• CAS: 151636-74-7
• 化学式: C₂₀H₁₅N₃O₆
• 分子量: 393.356
• InChiKey: VHXNKPBCCMUMSW-HXUWFJFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  29
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  126
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  9-nitro-(20R)-camptothecin 在 盐酸 、 tin(ll) chloride 作用下， 反应 1.5h， 以57%的产率得到9-amino-(20R)-camptothecin
  参考文献：
  名称：

  植物抗肿瘤剂。30.新型喜树碱类似物的合成和结构活性。

  摘要：

  已经制备了具有许多环A取代基的20S，20RS和20R构型的大量喜树碱（CPT）类似物。拓扑异构酶I（TI）抑制数据（IC50）已通过标准程序获得。通常，具有20S构型的化合物在9或10位上被氨基，卤代或羟基取代会导致TI抑制作用增强。20RS构型的化合物在体外和体内活性较低，而20R构型的化合物则无活性。在TI抑制试验中，在A环上具有10,11-亚甲二氧基取代的化合物显示出显着的效能增强。在包括L-1210小鼠白血病测定法在内的各种体内测定法中确定的某些类似物的活性通常与TI抑制作用一致。制备了许多水溶性类似物，例如20-甘氨酸酯，9-甘氨酰胺或水解的内酯盐，并在体外和体内试验中进行了测试。通常，就L-1210分析中的TI抑制作用和寿命延长而言，这些化合物的活性均不如CPT。然而，某些20-甘氨酸酯在静脉内给药后显示出良好的体内活性。

  DOI：

  10.1021/jm00070a013
• 作为产物：
  描述：

  2,6-dinitrobenzaldehyde ethylene acetal 在 盐酸 、 sodium sulfide 、 硫酸 、 溶剂黄146 作用下， 以 四氢呋喃 、 乙醇 、 水 为溶剂， 反应 5.5h， 生成 9-nitro-(20R)-camptothecin
  参考文献：
  名称：

  植物抗肿瘤剂。30.新型喜树碱类似物的合成和结构活性。

  摘要：

  已经制备了具有许多环A取代基的20S，20RS和20R构型的大量喜树碱（CPT）类似物。拓扑异构酶I（TI）抑制数据（IC50）已通过标准程序获得。通常，具有20S构型的化合物在9或10位上被氨基，卤代或羟基取代会导致TI抑制作用增强。20RS构型的化合物在体外和体内活性较低，而20R构型的化合物则无活性。在TI抑制试验中，在A环上具有10,11-亚甲二氧基取代的化合物显示出显着的效能增强。在包括L-1210小鼠白血病测定法在内的各种体内测定法中确定的某些类似物的活性通常与TI抑制作用一致。制备了许多水溶性类似物，例如20-甘氨酸酯，9-甘氨酰胺或水解的内酯盐，并在体外和体内试验中进行了测试。通常，就L-1210分析中的TI抑制作用和寿命延长而言，这些化合物的活性均不如CPT。然而，某些20-甘氨酸酯在静脉内给药后显示出良好的体内活性。

  DOI：

  10.1021/jm00070a013

文献信息

• ADJUVANT IMMUNOTHERAPY FOR THE PREVENTIVE, CURATIVE OR PALLIATIVE TREATMENT OF CHRONIC SYSTEMIC DISEASES SUCH AS CANCER, OF CLINICAL MANIFESTATIONS ASSOCIATED WITH THESE DISEASES, SUCH AS CACHEXIA, AND REMEDYING ADVERSE EFFECTS OF DRUGS AND TREATMENTS, SUCH AS IMMUNODEPRESSION, NEUTROPENIA AND LYMPHOCYTOPENIA, COMPRISING THE ASSOCIATION OR COMBINATION OF A SPECIALLY SELECTED BIOLOGICAL RESPONSE MODIFIER AND OTHER ANTINEOPLASTIC COMPOUNDS AND/OR OTHER TREATMENTS
  申请人：Nunes, Iseu Da Silva

  公开号：EP2514483A1

  公开（公告）日：2012-10-24

  The present invention comprises a new combination or association of pharmacologically active substances and/or non-drug treatments for chronic systemic diseases such as cancer. According to the present invention, the combination or association of substances and/or non-drug treatments is used to treat cancer, clinical problems associated to cancer and adverse side effects related to substances and/or treatments used to fight this illness. The components of the combination or association of substances, the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance and/or treatment with antineoplastic properties can be jointly or simultaneously or consecutively or sequentially administered in an appropriate form, according to their chemical properties, and with the use of the most suitable procedures, and also in the most therapeutically effective dose and use.

  本发明包括一种新的药理活性物质和/或非药物疗法的组合或联合，用于治疗慢性系统性疾病，如癌症。根据本发明，物质和/或非药物疗法的组合或组合物用于治疗癌症、与癌症相关的临床问题以及与用于抗击这种疾病的物质和/或疗法相关的不良副作用。物质组合或组合的成分、生物反应调节剂（磷脂酰-棕榈油酸酐铵和镁的蛋白聚合体）和至少一种具有抗肿瘤特性的物质和/或治疗方法可以根据其化学特性，以适当的形式联合或同时或连续或依次给药，并采用最合适的程序，以及最有效的治疗剂量和用法。
• CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES
  申请人：Oxalys Pharmaceuticals

  公开号：EP3238724A2

  公开（公告）日：2017-11-01

  Glycyrrhetinic acid analogs for use in treating neurodegenerative alpha-synuclein aggregation diseases and disorders such as Parkinson's disease.

  用于治疗神经退行性α-突触核蛋白聚集性疾病和帕金森病等失调症的甘草次酸类似物。
• USE OF COMPOUNDS FOR THE TREATMENT OF PAIN
  申请人：Akron Molecules AG

  公开号：EP2846788A1

  公开（公告）日：2015-03-18
• ADJUVANT IMMUNOTHERAPY FOR THE PREVENTIVE, CURATIVE OR PALLIATIVE TREATMENT OF CHRONIC SYSTEMIC DISEASES SUCH AS CANCER, OF CLINICAL MANIFESTATIONS ASSOCIATED WITH DISEASES LIKE CACHEXIA AND CORRECTION OF ADVERSE EFFECTS OF DRUGS SUCH AS IMMUNOSUPPRESSION, NEUTROPENIA AND LYMPHOPENIA, COMPRISING THE ASSOCIATION OR COMBINATION OF A BIOLOGICAL RESPONSE MODIFIER SPECIALLY SELECTED AND OTHER SUBSTANCES WITH ANTINEOPLASTIC ACTION AND/OR OTHER TREATMENTS
  申请人：Nunes Iseu da Silva

  公开号：US20120251441A1

  公开（公告）日：2012-10-04

  The present invention comprises a new combination or association of pharmacologically active substances and/or non-drug treatments for chronic systemic diseases such as cancer. According to the present invention, the combination or association of substances and/or non-drug treatments is used to treat cancer, clinical problems associated to cancer and adverse side effects related to substances and/or treatments used to fight this illness. The components of the combination or association of substances, the biological response modifier (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance and/or treatment with antineoplastic properties can be jointly or simultaneously or consecutively or sequentially administered in an appropriate form, according to their chemical properties, and with the use of the most suitable procedures, and also in the most therapeutically effective dose and use.
• US7790905B2
  申请人：——

  公开号：US7790905B2

  公开（公告）日：2010-09-07